Globus Medical (GMED) 10-Q 31 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 27, 2014
Document Information	'	'
Entity Registrant Name	'GLOBUS MEDICAL INC	'
Entity Central Index Key	'0001237831	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	94,476,797

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
ASSETS	'	'
Cash and cash equivalents	$169,449	$89,962
Short-term marketable securities	129,302	148,962
Accounts receivable, net of allowances of $1,733 and $1,581, respectively	62,598	62,414
Inventories	77,430	70,350
Prepaid expenses and other current assets	6,183	5,080
Income taxes receivable	2,101	2,723
Deferred income taxes	37,750	37,317
Total current assets	484,813	416,808
Property and equipment, net of accumulated depreciation of $113,868 and $99,910, respectively	66,062	64,150
Long-term marketable securities	47,028	36,528
Intangible assets, net	29,139	29,537
Goodwill	18,372	18,372
Other assets	1,025	909
Total assets	646,439	566,304
LIABILITIES AND EQUITY	'	'
Accounts payable	9,703	10,073
Accounts payable to related-party	3,945	2,656
Accrued expenses	55,606	51,125
Income taxes payable	2,062	2,358
Business acquisition liabilities, current	1,443	1,730
Total current liabilities	72,759	67,942
Business acquisition liabilities, net of current portion	15,348	15,528
Deferred income taxes	1,734	6,385
Other liabilities	2,790	4,089
Total liabilities	92,631	93,944
Commitments and contingencies (Note 12)	'	'
Equity:	'	'
Common stock; $0.001 par value. Authorized 785,000 shares; issued and outstanding 94,464 and 93,443 shares at September 30, 2014 and December 31, 2013, respectively	94	93
Additional paid-in capital	170,885	153,987
Accumulated other comprehensive loss	-1,307	-1,009
Retained earnings	384,136	319,289
Total equity	553,808	472,360
Total liabilities and equity	$646,439	$566,304

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Current Assets:	'	'
Allowance for doubtful accounts	$1,733	$1,581
Property, Plant and Equipment, Net	'	'
Accumulated depreciation	$113,868	$99,910
Equity:	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	785,000,000	785,000,000
Common stock, shares issued	94,464,265	93,442,753
Common stock, shares outstanding	94,464,265	93,442,753

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Sales	$117,787	$107,187	$345,570	$319,214
Cost of goods sold	27,686	25,315	79,581	72,309
Provision for litigation - cost of goods sold	0	0	0	1,260
Gross profit	90,101	81,872	265,989	245,645
Operating expenses:	'	'	'	'
Research and development	8,146	6,568	23,283	20,452
Selling, general and administrative	46,986	45,702	140,089	136,849
Provision for litigation	46	99	3,899	18,418
Total operating expenses	55,178	52,369	167,271	175,719
Operating Income	34,923	29,503	98,718	69,926
Other income/(expense), net	-124	197	446	255
Income before income taxes	34,799	29,700	99,164	70,181
Income tax provision	11,738	9,390	34,317	22,554
Net Income	$23,061	$20,310	$64,847	$47,627
Earnings per share:	'	'	'	'
Basic	$0.24	$0.22	$0.69	$0.52
Diluted	$0.24	$0.22	$0.68	$0.51
Weighted average shares outstanding:	'	'	'	'
Basic	94,399	93,028	94,111	92,418
Dilutive stock options	1,076	1,394	1,267	1,626
Diluted	95,475	94,422	95,378	94,044
Anti-dilutive stock equivalents excluded from weighted average calculation	1,660	1,622	1,518	2,084

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income	$23,061	$20,310	$64,847	$47,627
Other comprehensive income/(loss):	'	'	'	'
Unrealized gain/(loss) on marketable securities, net of tax	-18	72	-8	13
Foreign currency translation gain/(loss)	-422	175	-290	-371
Total other comprehensive income/(loss)	-440	247	-298	-358
Comprehensive Income	$22,621	$20,557	$64,549	$47,269

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income	$64,847	$47,627
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	16,057	14,211
Amortization of premium on marketable securities	2,073	1,476
Provision for excess and obsolete inventories	5,439	6,405
Stock-based compensation	5,211	3,865
Allowance for doubtful accounts	236	234
Change in deferred income taxes	-5,115	-11,138
(Increase)/decrease in:	'	'
Accounts receivable	-886	-2,143
Inventories	-12,535	-15,715
Prepaid expenses and other assets	-1,325	-3,587
Increase/(decrease) in:	'	'
Accounts payable	-2,253	1,022
Accounts payable to related-party	1,289	730
Accrued expenses and other liabilities	3,855	19,639
Income taxes payable/receivable	334	-1,813
Net cash provided by operating activities	77,227	60,813
Cash flows from investing activities:	'	'
Purchases of marketable securities	-161,149	-186,748
Maturities of marketable securities	144,207	19,000
Sales of marketable securities	24,028	4,979
Purchases of property and equipment	-15,659	-18,475
Net cash used in investing activities	-8,573	-181,244
Cash flows from financing activities:	'	'
Payment of business acquisition liabilities	-900	-1,000
Proceeds from issuance of common stock	7,644	6,221
Excess tax benefit related to nonqualified stock options	4,044	4,519
Net cash provided by financing activities	10,788	9,740
Effect of foreign exchange rate on cash	45	198
Net increase/(decrease) in cash and cash equivalents	79,487	-110,493
Cash and cash equivalents, beginning of period	89,962	212,400
Cash and cash equivalents, end of period	169,449	101,907
Supplemental disclosures of cash flow information:	'	'
Interest paid	32	42
Income taxes paid	$36,362	$30,956

BACKGROUND_AND_SUMMARY_OF_SIGN

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Background and Summary of Significant Accounting Policies	'
	BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) The Company
	Globus Medical, Inc., together with its subsidiaries, is a medical device company focused exclusively on the design, development and commercialization of musculoskeletal implants. We are currently focused on implants that promote healing in patients with spine disorders. Since our inception in 2003, we have launched over 130 products and offer a product portfolio addressing a broad array of spinal pathologies.
	We are headquartered in Audubon, Pennsylvania and market and sell our products through our exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
	The terms “the Company,” “Globus,” “we,” “us” and “our” refer to Globus Medical, Inc. and, where applicable, our consolidated subsidiaries.
	(b) Basis of Presentation
	The accompanying interim unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	In the opinion of management, the statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results for the three- and nine-month periods presented. The results of operations for any interim period are not indicative of results for the full year. Certain reclassifications have been made to prior period statements to conform to the current year presentation.
	(c) Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held. All intercompany balances and transactions are eliminated in consolidation.
	(d) Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
	(e) Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper, securities of U.S. government-sponsored agencies and asset-backed securities, and are classified as available-for-sale as of September 30, 2014. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
	(f) Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
	(g) Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.
	(h) Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) released a standard on the recognition of revenue from contracts with customers that is designed to create greater comparability for financial statement users across industries and jurisdictions. Under the new standard, an entity will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the payment to which the entity expects to be entitled in exchange for those goods or services. The standard also will require enhanced disclosures and provide more comprehensive guidance for transactions such as service revenue and contract modifications. The standard will take effect for public companies for annual reporting periods beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. We are currently evaluating the impact of the new standard on our financial position, results of operations and disclosures.

ACQUISITIONS

ACQUISITIONS	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure	'
	ACQUISITIONS
	On December 23, 2013, we entered into an asset purchase agreement with a small robotics development company, pursuant to which we acquired substantially all of its assets for $16.8 million. In addition to the initial purchase price, we may be obligated to make a milestone payment and revenue sharing payments based upon a percentage of net sales of certain products based on the intellectual property we acquired in the transaction. The acquired company was privately held and is focused on developing a next generation surgical robotic positioning platform for spine, brain and other therapeutic markets. The technology is intended to enable surgeons to perform minimally invasive and percutaneous surgical procedures with greater accuracy, safety and reproducibility than is currently available. We accounted for this purchase as a business combination, and as a result, recorded goodwill of $3.0 million.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2014
Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure	'
	INTANGIBLE ASSETS
	A summary of intangible assets as of September 30, 2014 is presented below:
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Customer relationships & other intangibles	9.5	3,623		(1,156		)	2,467
	Patents	17	2,420		(308		)	2,112
	Total intangible assets		$	30,603	$	(1,464	)	$	29,139
	A summary of intangible assets as of December 31, 2013 is presented below:
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Customer relationships & other intangibles	9.5	3,623		(864		)	2,759
	Patents	17	2,420		(202		)	2,218
	Total intangible assets		$	30,603	$	(1,066	)	$	29,537

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	9 Months Ended
	Sep. 30, 2014
Marketable Securities [Abstract]	'
Marketable Securities	'
	MARKETABLE SECURITIES
	The composition of our short-term and long-term marketable securities as of September 30, 2014 is as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	26,396	$	10	$	—		$	26,406
	Corporate debt securities	Less than 1	61,060		29		(2		)	61,087
	Commercial paper	Less than 1	41,415		8		(1		)	41,422
	Asset-backed securities	Less than 1	387		—		—			387
	Total short-term marketable securities		$	129,258	$	47	$	(3	)	$	129,302
	Long-term:
	Municipal bonds	2-Jan	$	5,686	$	3	$	—		$	5,689
	Corporate debt securities	2-Jan	18,436		1		(10		)	18,427
	Asset-backed securities	2-Jan	16,912		4		(2		)	16,914
	Securities of U.S. government-sponsored agencies	2-Jan	5,999		1		(2		)	5,998
	Total long-term marketable securities		$	47,033	$	9	$	(14	)	$	47,028
	Our short-term and long-term marketable securities as of December 31, 2013 were as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	77,342	$	17	$	(15	)	$	77,344
	Corporate debt securities	Less than 1	35,525		15		(11		)	35,529
	Commercial paper	Less than 1	36,083		6		—			36,089
	Total short-term marketable securities		$	148,950	$	38	$	(26	)	$	148,962
	Long-term:
	Municipal bonds	2-Jan	$	12,304	$	13	$	(1	)	$	12,316
	Corporate debt securities	2-Jan	17,533		27		—			17,560
	Asset-backed securities	2-Jan	6,651		2		(1		)	6,652
	Total long-term marketable securities		$	36,488	$	42	$	(2	)	$	36,528

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	FAIR VALUE MEASUREMENTS
	Under the accounting for fair value measurements and disclosures, fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:
	Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities;
	Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and
	Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques.
	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	September 30,		Level 1		Level 2		Level 3
		2014
	Assets
	Cash equivalents	$	55,735	$	52,077	$	3,658	$	—
	Municipal bonds	32,095		—		32,095		—
	Corporate debt securities	79,514		—		79,514		—
	Commercial paper	41,422		—		41,422		—
	Asset-backed securities	17,301		—		17,301		—
	Securities of U.S. government-sponsored agencies	5,998		—		5,998		—
	Liabilities
	Acquisition-related contingent consideration	14,515		—		—		14,515
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2013
	Assets
	Cash equivalents	$	20,363	$	800	$	19,563	$	—
	Municipal bonds	89,660		—		89,660		—
	Corporate debt securities	53,089		—		53,089		—
	Commercial paper	36,089		—		36,089		—
	Asset-backed securities	6,652		—		6,652		—
	Liabilities
	Acquisition-related contingent consideration	14,177		—		—		14,177
	Acquisition-related contingent consideration represents our contingent milestone, performance and revenue-sharing payment obligations related to our acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of acquisition-related contingent consideration uses assumptions we believe would be made by a market participant. We assess these estimates on an ongoing basis as additional data impacting the assumptions is obtained. Changes in the fair value of acquisition-related contingent consideration related to updated assumptions and estimates are recognized within research and development and selling, general and administrative expenses in the consolidated statements of income.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	INVENTORIES
	(In thousands)	September 30,		December 31, 2013
		2014
	Raw materials	$	2,175	$	1,369
	Work in process	2,589		2,820
	Finished goods	72,666		66,161
	Total inventories	$	77,430	$	70,350

ACCRUED_EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	ACCRUED EXPENSES
	(In thousands)	September 30,		December 31,
		2014		2013
	Compensation and other employee-related costs	$	16,609	$	17,428
	Legal and other settlements and expenses	26,044		23,765
	Non-income taxes	4,502		2,938
	Other	8,451		6,994
	Total accrued expenses	$	55,606	$	51,125

DEBT

DEBT	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	DEBT
	Line of Credit
	In May 2011, we entered into a credit agreement with Wells Fargo Bank related to a revolving credit facility that provided for borrowings up to $50.0 million. At our request, and with the approval of the bank, the amount of borrowings available under the revolving credit facility can be increased to $75.0 million. The revolving credit facility includes up to a $25.0 million sub-limit for letters of credit. As amended to date, the revolving credit facility was extended to May 2015. Cash advances bear interest at our option either at a fluctuating rate per annum equal to the daily LIBOR in effect for a one-month period plus 0.75%, or a fixed rate for a one- or three-month period equal to LIBOR plus 0.75%. The credit agreement governing the revolving credit facility also subjects us to various restrictive covenants, including the requirement to maintain maximum consolidated leverage. The covenants also include limitations on our ability to repurchase shares, to pay cash dividends or to enter into a sale transaction. As of September 30, 2014, we were in compliance with all covenants under the credit agreement, there were no outstanding borrowings under the revolving credit facility and available borrowings were $50.0 million. We may terminate the credit agreement at any time on ten days’ notice without premium or penalty.

EQUITY

EQUITY	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Equity	'
	EQUITY
	Our amended and restated Certificate of Incorporation provides for a total of 785,000,000 authorized shares of common stock. Of the authorized number of shares of common stock, 500,000,000 shares are designated as Class A common stock (“Class A Common”), 275,000,000 shares are designated as Class B common stock (“Class B Common”) and 10,000,000 shares are designated as Class C common stock (“Class C Common”).
	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common			Class B		Total
					Common
	September 30, 2014	70,586,709			23,877,556		94,464,265
	December 31, 2013	66,065,197			27,377,556		93,442,753
	The following table summarizes changes in total equity:
		Nine Months Ended
	(In thousands)	September 30,
		2014
	Total equity, beginning of period	$	472,360
	Net income	64,847
	Stock-based compensation	5,211
	Exercise of stock options	7,644
	Excess tax benefit of nonqualified stock options	4,044
	Other comprehensive loss	(298		)
	Total equity, end of period	$	553,808
	The tables below present the changes in each component of accumulated other comprehensive income/(loss), including current period other comprehensive income/(loss) and reclassifications out of accumulated other comprehensive income/(loss):
	(In thousands)			Unrealized gain on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive income/(loss), net of tax, at December 31, 2013			$	32		$	(1,041	)	$	(1,009	)
	Other comprehensive loss before reclassifications			(15		)	(290		)	(305		)
	Amounts reclassified from accumulated other comprehensive income, net of tax			7			—			7
	Other comprehensive loss, net of tax			(8		)	(290		)	(298		)
	Accumulated other comprehensive income/(loss), net of tax, at September 30, 2014			$	24		$	(1,331	)	$	(1,307	)
	(In thousands)			Unrealized loss on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive loss, net of tax, at December 31, 2012			$	—		$	(767	)	$	(767	)
	Other comprehensive income/(loss) before reclassifications			17			(371		)	(354		)
	Amounts reclassified from accumulated other comprehensive income/(loss), net of tax			(4		)	—			(4		)
	Other comprehensive income/(loss), net of tax			13			(371		)	(358		)
	Accumulated other comprehensive income/(loss), net of tax, at September 30, 2013			$	13		$	(1,138	)	$	(1,125	)

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	STOCK-BASED COMPENSATION
	We have three stock plans, but no additional shares will be issued under our Amended and Restated 2003 Stock Plan and our 2008 Stock Plan, leaving the 2012 Equity Incentive Plan (the "2012 Plan") as the only remaining active stock plan.  The purpose of these stock plans was, and the 2012 Plan is, to provide incentive to employees, directors, and consultants of Globus.  The Plans are administered by the Board of Directors of Globus (the “Board”) or its delegates. The number, type of option, exercise price, and vesting terms are determined by the Board or its delegates in accordance with the terms of the Plans. The options granted expire on a date specified by the Board, but generally not more than ten years from the grant date. Option grants to employees generally vest monthly over a four-year period.
	The 2012 Plan was approved by our Board in March 2012, and by our stockholders in June 2012. Under the 2012 Plan, the aggregate number of shares of Class A Common that may be issued subject to options and other awards is equal to the sum of (i) 3,076,923 shares, (ii) any shares available for issuance under the 2008 Plan as of March 13, 2012, (iii) any shares underlying awards outstanding under the 2008 Plan as of March 13, 2012 that, on or after that date, are forfeited, terminated, expired or lapse for any reason, or are settled for cash without delivery of shares and (iv) starting January 1, 2013, an annual increase in the number of shares available under the 2012 Plan equal to up to 3% of the number of shares of our common and preferred stock outstanding at the end of the previous year, as determined by our Board. The number of shares that may be issued or transferred pursuant to incentive stock options under the 2012 Plan is limited to 10,769,230 shares. The shares of Class A Common covered by the 2012 Plan are authorized but unissued shares, treasury shares or shares of common stock purchased on the open market.
	As of September 30, 2014, there were 6,277,749 shares of common stock available for future grants under the 2012 Plan.
	The weighted average grant date per share fair values of the options awarded to employees were as follows:
		Three Months Ended						Nine Months Ended
		September 30,			September 30,			September 30,			September 30,
		2014			2013			2014			2013
	Weighted average grant date per share fair value	$	7.73		$	7.17		$	9.88		$	6.05
	Stock option activity during the nine months ended September 30, 2014 is summarized as follows:
		Option Shares(thousands)		Weighted average exercise price			Weighted average remaining contractual life (years)		Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2013	4,886		$	10.04
	Granted	1,167		23.73
	Exercised	(1,022	)	7.48
	Forfeited	(190	)	15.12
	Outstanding at September 30, 2014	4,841		$	13.69		7.1		$	33,679
	Exercisable at September 30, 2014	2,473		$	8.76		5.5		$	26,984
	Compensation expense related to stock options granted to employees and non-employees under our stock plans and the intrinsic value of stock options exercised was as follows:
		Three Months Ended						Nine Months Ended
	(In thousands)	September 30,			September 30,			September 30,			September 30,
		2014			2013			2014			2013
	Compensation expense related to stock options	$	1,661		$	1,387		$	5,211		$	3,865
	Intrinsic value of stock options exercised	853			5,027			16,750			22,326
	As of September 30, 2014, there was $15.5 million of unrecognized compensation expense related to unvested employee stock options that are expected to vest over a weighted average period of three years.

INCOME_TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	INCOME TAXES
	In computing our income tax provision, we make certain estimates and management judgments, such as estimated annual taxable income or loss, annual effective tax rate, the nature and timing of permanent and temporary differences between taxable income for financial reporting and tax reporting, and the recoverability of deferred tax assets. Our estimates and assumptions may change as new events occur, additional information is obtained, or as the tax environment changes. Should facts and circumstances change during a quarter causing a material change to the estimated effective income tax rate, a cumulative adjustment is recorded.
		Three Months Ended				Nine Months Ended
		September 30,		September 30,		September 30,		September 30,
		2014		2013		2014		2013
	Effective income tax rate	33.7	%	31.6	%	34.6	%	32.1	%
	Our tax provision and effective rates for the three and nine months ended September 30, 2014 were primarily affected by a reduction in uncertain tax positions related to Internal Revenue Service audits of our 2011 and 2012 tax years, resulting in no adjustments, offset partially by the research and experimentation credit not being extended. As of September 30, 2014, the research and experimentation credit has not been extended for 2014, having an estimated 0.8% impact to the effective rate for the year. The tax provision and effective rate for the three months ended September 30, 2013 were primarily affected by disqualifying dispositions and the existence of the research and experimentation credit that was passed as part of the American Taxpayer Relief Act of 2012 (“ATRA”) for 2013, while the tax provision and effective rate for the nine months ended September 30, 2013 were primarily affected by the litigation charges and the timing of the ATRA.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	We are involved in a number of proceedings, legal actions, and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within our control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions prohibiting us from engaging in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. We record a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. While it is not possible to predict the outcome for most of the matters discussed, we believe it is possible that costs associated with them could have a material adverse impact on our consolidated earnings, financial position or cash flows.
	N-Spine, Synthes and DePuy Synthes Litigation
	In April 2010, N-Spine, Inc. and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. N-Spine, the patent owner, and Synthes USA, a licensee of the subject patent, allege that we infringe one or more claims of the patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. N-Spine and Synthes USA seek injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. This matter was stayed on July 14, 2011 pending the resolution of an inter partes reexamination on the asserted patent granted by the U.S. Patent and Trademark Office (“USPTO”) in February 2011. In December 2011, the examiner withdrew the original grounds of rejection of the asserted patent and we have appealed the examiner’s decision. In January 2014, the USPTO ruled on the appeal finding certain claims rejected in view of the prior art and affirming certain other claims. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	In a related matter, on January 8, 2014, Depuy Synthes Products, LLC (“Depuy Synthes”) filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Depuy Synthes alleges that we infringe one or more claims of the asserted patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. Depuy Synthes seeks injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. This matter is in its very early stages, and the probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC Litigation
	In July 2011, Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Synthes USA LLC, the patent owner, Synthes USA Products, LLC, a licensee to manufacture products of the subject patents, and Synthes USA Sales LLC, a licensee to sell products of the subject patents, allege that we infringed one or more claims of three patents by making, using, offering for sale or selling our COALITION®, INDEPENDENCE® and INTERCONTINENTAL® products. As a result of the acquisition of Synthes, Inc. by Johnson & Johnson, a motion was filed to change the plaintiff in this matter to DePuy Synthes in February 2013. On June 14, 2013, the jury in this case returned a verdict, finding that prior versions of the three products we previously sold did infringe on DePuy Synthes’ patents and awarding monetary damages in the amount of $16.0 million. The jury also upheld the validity of DePuy Synthes’ patents. There was no finding of willful infringement by Globus. This verdict does not impact our ability to conduct our business or have any material impact on our future revenues.
	We believe the facts and the law do not support the jury’s findings of infringement and patent validity and are seeking to overturn the verdict through the appeals process.
	As of December 31, 2013, we accrued $19.5 million in damages and other litigation-related costs related to this case, of which $1.3 million was included in provision for litigation - cost of goods sold (due to a write off of certain inventory which will not be sold due to the verdict) and $18.2 million was included in provision for litigation (operating expense). During the nine months ended September 30, 2014, we accrued an additional $0.5 million in interest included in provision for litigation related to this litigation.
	L5 Litigation
	In December 2009, we filed suit in the Court of Common Pleas of Montgomery County, Pennsylvania against our former exclusive independent distributor L5 Surgical, LLC and its principals, seeking an injunction and declaratory judgment concerning certain restrictive covenants made to L5 by its sales representatives. L5 brought counterclaims against us alleging tortious interference, unfair competition and conspiracy. The injunction phase was resolved in September 2010, and this matter is now in the discovery phase of litigation on the underlying damages claims. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	NuVasive Infringement Litigation
	In October 2010, NuVasive, Inc. filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. NuVasive, the patent owner, alleges that we infringe one or more claims of three patents by making, using, offering for sale or selling our MARS 3V™ retractor for use in certain lateral fusion procedures. NuVasive seeks injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. Additionally, we sought inter partes reexaminations of the three patents asserted by NuVasive in the USPTO, which were granted in April 2012. In August 2012, the examiner withdrew the original grounds of rejection of the patents asserted by NuVasive, and we are in the process of appealing the examiner’s decision. In June 2014, the USPTO found that the claims of one of the three patents are invalid and found that the claims of the second of the three patents are affirmed as valid. The appeal of the third patent is still pending. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	NuVasive Employee Litigation
	We have hired several employees who were formerly employed by NuVasive, Inc. In July 2011, NuVasive filed suit against us in the District Court of Travis County, Texas alleging that our hiring of one named former employee and other unnamed former employees constitutes tortious interference with its contracts with those employees, and with prospective business relationships, as well as aiding and abetting the breach of fiduciary duty. NuVasive is seeking compensatory damages, permanent injunction, punitive damages and attorneys’ fees. Trial is currently scheduled for February 2015. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	Bianco Litigation
	On March 21, 2012, Sabatino Bianco filed suit against us in the Federal District Court for the Eastern District of Texas claiming that we misappropriated his trade secret and confidential information and improperly utilized it in developing our CALIBER® product. Bianco alleges that we engaged in misappropriation of trade secrets, breach of contract, unfair competition, fraud and theft and seeks correction of inventorship, injunctive relief and exemplary damages. On April 20, 2012, Bianco filed a motion for a preliminary injunction, seeking to enjoin us from making, using, selling, importing or offering for sale our CALIBER® product. On November 15, 2012, the court denied Bianco’s motion for preliminary injunction. On October 1, 2013, Bianco amended his complaint to claim that his trade secrets and confidential information were also used improperly in developing our RISE® and CALIBER-L® products.
	On January 17, 2014, the jury in this case returned a verdict in favor of Bianco on a claim of misappropriation of trade secret. We accrued the verdict amount of $4.3 million as of December 31, 2013. The jury found against Bianco on the claims of breach of contract and disgorgement of profits. The court granted our motion for judgment as a matter of law and dismissed Bianco’s claims for unfair competition, fraud, and exemplary damages, and Bianco abandoned the claim of misappropriation of confidential information. Bianco’s claims of correction of inventorship, unjust enrichment, and permanent injunctive relief were not submitted to the jury. On March 7, 2014, the court denied Bianco’s claim for correction of inventorship and ruled he is not entitled to be named as a co-inventor on any of the patents at issue, and also denied his claim for unjust enrichment. On March 17, 2014, the court denied Bianco’s claim for permanent injunctive relief. On July 2, 2014, the court awarded Bianco an ongoing royalty of 5% of the net sales of the CALIBER®, CALIBER-L®, and RISE® products, or products that are not colorably different from those products, for a fifteen year period on sales starting on January 18, 2014. The court entered final judgment on the jury verdict on July 17, 2014. Post-trial motions were denied on October 27, 2014.
	We do not expect the verdict to impact our ability to conduct our business or to have any material impact on our future revenues. We believe the facts and the law do not support the jury’s findings of misappropriation of trade secret and will seek to overturn the verdict through the appeals process.
	Altus Partners, LLC Litigation
	On February 20, 2013, Altus Partners, LLC filed suit against us in the U.S. District Court for the Eastern District of Pennsylvania for patent infringement. On April 7, 2014, we settled the litigation with Altus Partners and recognized a provision for litigation of $2.0 million.
	In addition, we are subject to legal proceedings arising in the ordinary course of business.

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related-Party Transactions	'
	RELATED-PARTY TRANSACTIONS
	We have contracted with a third-party manufacturer in which certain of our senior management and significant stockholders have or had ownership interests and leadership positions.
	We have purchased the following amounts of products and services from the supplier:
		Three Months Ended				Nine Months Ended
	(In thousands)	September 30,		September 30,		September 30,		September 30,
		2014		2013		2014		2013
	Purchases from related-party supplier	$	5,163	$	4,478	$	15,954	$	15,987
	As of September 30, 2014 and December 31, 2013, we had $3.9 million and $2.7 million, respectively, of accounts payable due to the supplier.

SEGMENT_AND_GEOGRAPHIC_INFORMA

SEGMENT AND GEOGRAPHIC INFORMATION	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment And Geographic Information	'
	SEGMENT AND GEOGRAPHIC INFORMATION
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We globally manage the business within one reportable segment. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Products are sold principally in the United States.
	The following table represents total sales by geographic area, based on the location of the customer:
		Three Months Ended				Nine Months Ended
	(In thousands)	September 30,		September 30,		September 30,		September 30,
		2014		2013		2014		2013
	United States	$	106,601	$	98,109	$	309,937	$	292,487
	International	11,186		9,078		35,633		26,727
	Total sales	$	117,787	$	107,187	$	345,570	$	319,214
	We classify our products into two categories: innovative fusion products and disruptive technology products. The following table represents total sales by product category:
		Three Months Ended				Nine Months Ended
	(In thousands)	September 30,		September 30,		September 30,		September 30,
		2014		2013		2014		2013
	Innovative Fusion	$	67,726	$	62,620	$	200,356	$	186,929
	Disruptive Technology	50,061		44,567		145,214		132,285
	Total sales	$	117,787	$	107,187	$	345,570	$	319,214

SUBSEQUENT_EVENTS_Notes

SUBSEQUENT EVENTS (Notes)	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	SUBSEQUENT EVENTS
	On October 23, 2014, we acquired 100% of the equity interests of Transplant Technologies of Texas, Ltd. (“TTOT”) for $35 million in cash. In addition to the initial purchase price, we may be obligated to make various working capital adjustments and milestone payments of up to $15 million based on sales thresholds from the product lines we acquired. Based in San Antonio, TTOT was a privately held allograft tissue processor focused on providing human tissue products including bone allografts, biomaterials and soft tissue products for the orthopedics markets. These products will complement our existing biologics product portfolio and represents a step in fulfilling our strategy of building a broad business in regenerative biologics. TTOT’s products and capabilities will assist in positioning us in existing allograft markets while also providing a dedicated source of supply for our pipeline of products utilizing human allograft tissue.

BACKGROUND_AND_SUMMARY_OF_SIGN1

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2014
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held. All intercompany balances and transactions are eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
Marketable Securities	'
	Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper, securities of U.S. government-sponsored agencies and asset-backed securities, and are classified as available-for-sale as of September 30, 2014. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
Revenue Recognition	'
	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2014
Intangible Assets Disclosure [Abstract]	'
Intangible Assets Acquired as Part of Business Combination	'
	A summary of intangible assets as of September 30, 2014 is presented below:
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Customer relationships & other intangibles	9.5	3,623		(1,156		)	2,467
	Patents	17	2,420		(308		)	2,112
	Total intangible assets		$	30,603	$	(1,464	)	$	29,139
	A summary of intangible assets as of December 31, 2013 is presented below:
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Customer relationships & other intangibles	9.5	3,623		(864		)	2,759
	Patents	17	2,420		(202		)	2,218
	Total intangible assets		$	30,603	$	(1,066	)	$	29,537

MARKETABLE_SECURITIES_Tables

MARKETABLE SECURITIES (Tables)	9 Months Ended
	Sep. 30, 2014
Marketable Securities [Abstract]	'
Marketable Securities	'
	The composition of our short-term and long-term marketable securities as of September 30, 2014 is as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	26,396	$	10	$	—		$	26,406
	Corporate debt securities	Less than 1	61,060		29		(2		)	61,087
	Commercial paper	Less than 1	41,415		8		(1		)	41,422
	Asset-backed securities	Less than 1	387		—		—			387
	Total short-term marketable securities		$	129,258	$	47	$	(3	)	$	129,302
	Long-term:
	Municipal bonds	2-Jan	$	5,686	$	3	$	—		$	5,689
	Corporate debt securities	2-Jan	18,436		1		(10		)	18,427
	Asset-backed securities	2-Jan	16,912		4		(2		)	16,914
	Securities of U.S. government-sponsored agencies	2-Jan	5,999		1		(2		)	5,998
	Total long-term marketable securities		$	47,033	$	9	$	(14	)	$	47,028
	Our short-term and long-term marketable securities as of December 31, 2013 were as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	77,342	$	17	$	(15	)	$	77,344
	Corporate debt securities	Less than 1	35,525		15		(11		)	35,529
	Commercial paper	Less than 1	36,083		6		—			36,089
	Total short-term marketable securities		$	148,950	$	38	$	(26	)	$	148,962
	Long-term:
	Municipal bonds	2-Jan	$	12,304	$	13	$	(1	)	$	12,316
	Corporate debt securities	2-Jan	17,533		27		—			17,560
	Asset-backed securities	2-Jan	6,651		2		(1		)	6,652
	Total long-term marketable securities		$	36,488	$	42	$	(2	)	$	36,528

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis	'
	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	September 30,		Level 1		Level 2		Level 3
		2014
	Assets
	Cash equivalents	$	55,735	$	52,077	$	3,658	$	—
	Municipal bonds	32,095		—		32,095		—
	Corporate debt securities	79,514		—		79,514		—
	Commercial paper	41,422		—		41,422		—
	Asset-backed securities	17,301		—		17,301		—
	Securities of U.S. government-sponsored agencies	5,998		—		5,998		—
	Liabilities
	Acquisition-related contingent consideration	14,515		—		—		14,515
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2013
	Assets
	Cash equivalents	$	20,363	$	800	$	19,563	$	—
	Municipal bonds	89,660		—		89,660		—
	Corporate debt securities	53,089		—		53,089		—
	Commercial paper	36,089		—		36,089		—
	Asset-backed securities	6,652		—		6,652		—
	Liabilities
	Acquisition-related contingent consideration	14,177		—		—		14,177

INVENTORIES_Tables

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	(In thousands)	September 30,		December 31, 2013
		2014
	Raw materials	$	2,175	$	1,369
	Work in process	2,589		2,820
	Finished goods	72,666		66,161
	Total inventories	$	77,430	$	70,350

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	(In thousands)	September 30,		December 31,
		2014		2013
	Compensation and other employee-related costs	$	16,609	$	17,428
	Legal and other settlements and expenses	26,044		23,765
	Non-income taxes	4,502		2,938
	Other	8,451		6,994
	Total accrued expenses	$	55,606	$	51,125

EQUITY_Tables

EQUITY (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Schedule of Issued and Outstanding Shares by Class	'
	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common			Class B	Total
					Common
	September 30, 2014	70,586,709			23,877,556	94,464,265
	December 31, 2013	66,065,197			27,377,556	93,442,753
Schedule of Stockholders Equity	'
	The following table summarizes changes in total equity:
		Nine Months Ended
	(In thousands)	September 30,
		2014
	Total equity, beginning of period	$	472,360
	Net income	64,847
	Stock-based compensation	5,211
	Exercise of stock options	7,644
	Excess tax benefit of nonqualified stock options	4,044
	Other comprehensive loss	(298		)
	Total equity, end of period	$	553,808

EQUITY_Accumulated_Other_Compr

EQUITY Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Accumulated Other Comprehensive Income/(Loss), Net of Tax	'
	The tables below present the changes in each component of accumulated other comprehensive income/(loss), including current period other comprehensive income/(loss) and reclassifications out of accumulated other comprehensive income/(loss):
	(In thousands)	Unrealized gain on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive income/(loss), net of tax, at December 31, 2013	$	32		$	(1,041	)	$	(1,009	)
	Other comprehensive loss before reclassifications	(15		)	(290		)	(305		)
	Amounts reclassified from accumulated other comprehensive income, net of tax	7			—			7
	Other comprehensive loss, net of tax	(8		)	(290		)	(298		)
	Accumulated other comprehensive income/(loss), net of tax, at September 30, 2014	$	24		$	(1,331	)	$	(1,307	)
	(In thousands)	Unrealized loss on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive loss, net of tax, at December 31, 2012	$	—		$	(767	)	$	(767	)
	Other comprehensive income/(loss) before reclassifications	17			(371		)	(354		)
	Amounts reclassified from accumulated other comprehensive income/(loss), net of tax	(4		)	—			(4		)
	Other comprehensive income/(loss), net of tax	13			(371		)	(358		)
	Accumulated other comprehensive income/(loss), net of tax, at September 30, 2013	$	13		$	(1,138	)	$	(1,125	)

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Grants in Period, Weighted Average Grant Date Fair Value	'
	The weighted average grant date per share fair values of the options awarded to employees were as follows:
		Three Months Ended						Nine Months Ended
		September 30,			September 30,			September 30,			September 30,
		2014			2013			2014			2013
	Weighted average grant date per share fair value	$	7.73		$	7.17		$	9.88		$	6.05
Summary of Stock Option Activity	'
	Stock option activity during the nine months ended September 30, 2014 is summarized as follows:
		Option Shares(thousands)		Weighted average exercise price			Weighted average remaining contractual life (years)		Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2013	4,886		$	10.04
	Granted	1,167		23.73
	Exercised	(1,022	)	7.48
	Forfeited	(190	)	15.12
	Outstanding at September 30, 2014	4,841		$	13.69		7.1		$	33,679
	Exercisable at September 30, 2014	2,473		$	8.76		5.5		$	26,984
Stock Option Compensation Expense and Intrinsic Value Schedule	'
	Compensation expense related to stock options granted to employees and non-employees under our stock plans and the intrinsic value of stock options exercised was as follows:
		Three Months Ended						Nine Months Ended
	(In thousands)	September 30,			September 30,			September 30,			September 30,
		2014			2013			2014			2013
	Compensation expense related to stock options	$	1,661		$	1,387		$	5,211		$	3,865
	Intrinsic value of stock options exercised	853			5,027			16,750			22,326

INCOME_TAXES_Tables

INCOME TAXES (Tables)	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Effective income tax rate [Table Text Block]	'
		Three Months Ended				Nine Months Ended
		September 30,		September 30,		September 30,		September 30,
		2014		2013		2014		2013
	Effective income tax rate	33.7	%	31.6	%	34.6	%	32.1	%

RELATEDPARTY_TRANSACTIONS_Tabl

RELATED-PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Schedule of Related-Party Transactions	'
	We have purchased the following amounts of products and services from the supplier:
		Three Months Ended				Nine Months Ended
	(In thousands)	September 30,		September 30,		September 30,		September 30,
		2014		2013		2014		2013
	Purchases from related-party supplier	$	5,163	$	4,478	$	15,954	$	15,987

SEGMENT_AND_GEOGRAPHIC_INFORMA1

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Revenue from External Customers by Geographical Area	'
	The following table represents total sales by geographic area, based on the location of the customer:
		Three Months Ended				Nine Months Ended
	(In thousands)	September 30,		September 30,		September 30,		September 30,
		2014		2013		2014		2013
	United States	$	106,601	$	98,109	$	309,937	$	292,487
	International	11,186		9,078		35,633		26,727
	Total sales	$	117,787	$	107,187	$	345,570	$	319,214
Revenue from External Customers by Products and Services	'
	The following table represents total sales by product category:
		Three Months Ended				Nine Months Ended
	(In thousands)	September 30,		September 30,		September 30,		September 30,
		2014		2013		2014		2013
	Innovative Fusion	$	67,726	$	62,620	$	200,356	$	186,929
	Disruptive Technology	50,061		44,567		145,214		132,285
	Total sales	$	117,787	$	107,187	$	345,570	$	319,214

BACKGROUND_AND_SUMMARY_OF_SIGN2

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (Minimum)	Sep. 30, 2014
Minimum	'
Summary of Significant Accounting Policies	'
Number of Products Launched Since Inception	130

ACQUISITIONS_Details

ACQUISITIONS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 23, 2013
			Acquisitions 2013
Business Acquisition	'	'	'
Net assets acquired	'	'	$16,800,000
Goodwill	$18,372,000	$18,372,000	$3,000,000

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Acquired Intangible Assets	'	'
Intangible assets, gross	$30,603	$30,603
Accumulated amortization	-1,464	-1,066
Intangible assets, net	29,139	29,537
Customer Relationships & Other Intangibles	'	'
Acquired Intangible Assets	'	'
Weighted average amortization period	'9 years 6 months	'9 years 6 months
Gross carrying amount	3,623	3,623
Accumulated amortization	-1,156	-864
Finite-lived intangible assets, net	2,467	2,759
Patents	'	'
Acquired Intangible Assets	'	'
Weighted average amortization period	'17 years	'17 years
Gross carrying amount	2,420	2,420
Accumulated amortization	-308	-202
Finite-lived intangible assets, net	2,112	2,218
In-Process Research & Development	'	'
Acquired Intangible Assets	'	'
Indefinite-lived intangible assets	$24,560	$24,560

MARKETABLE_SECURITIES_Details

MARKETABLE SECURITIES (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Short-term Marketable Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	$129,258	$148,950
Marketable Securities, Gross Unrealized Gains	47	38
Marketable Securities, Gross Unrealized Losses	-3	-26
Marketable Securities, Fair Value	129,302	148,962
Short-term Marketable Securities | Municipal Bonds	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	26,396	77,342
Marketable Securities, Gross Unrealized Gains	10	17
Marketable Securities, Gross Unrealized Losses	0	-15
Marketable Securities, Fair Value	26,406	77,344
Short-term Marketable Securities | Municipal Bonds | Maximum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'1 year	'1 year
Short-term Marketable Securities | Corporate Debt Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	61,060	35,525
Marketable Securities, Gross Unrealized Gains	29	15
Marketable Securities, Gross Unrealized Losses	-2	-11
Marketable Securities, Fair Value	61,087	35,529
Short-term Marketable Securities | Corporate Debt Securities | Maximum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'1 year	'1 year
Short-term Marketable Securities | Commercial Paper	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	41,415	36,083
Marketable Securities, Gross Unrealized Gains	8	6
Marketable Securities, Gross Unrealized Losses	-1	0
Marketable Securities, Fair Value	41,422	36,089
Short-term Marketable Securities | Commercial Paper | Maximum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'1 year	'1 year
Short-term Marketable Securities | Asset-backed Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	387	'
Marketable Securities, Gross Unrealized Gains	0	'
Marketable Securities, Gross Unrealized Losses	0	'
Marketable Securities, Fair Value	387	'
Short-term Marketable Securities | Asset-backed Securities | Maximum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'1 year	'
Long-term Marketable Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	47,033	36,488
Marketable Securities, Gross Unrealized Gains	9	42
Marketable Securities, Gross Unrealized Losses	-14	-2
Marketable Securities, Fair Value	47,028	36,528
Long-term Marketable Securities | Municipal Bonds	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	5,686	12,304
Marketable Securities, Gross Unrealized Gains	3	13
Marketable Securities, Gross Unrealized Losses	0	-1
Marketable Securities, Fair Value	5,689	12,316
Long-term Marketable Securities | Municipal Bonds | Minimum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'1 year	'1 year
Long-term Marketable Securities | Municipal Bonds | Maximum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'2 years	'2 years
Long-term Marketable Securities | Corporate Debt Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	18,436	17,533
Marketable Securities, Gross Unrealized Gains	1	27
Marketable Securities, Gross Unrealized Losses	-10	0
Marketable Securities, Fair Value	18,427	17,560
Long-term Marketable Securities | Corporate Debt Securities | Minimum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'1 year	'1 year
Long-term Marketable Securities | Corporate Debt Securities | Maximum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'2 years	'2 years
Long-term Marketable Securities | Asset-backed Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	16,912	6,651
Marketable Securities, Gross Unrealized Gains	4	2
Marketable Securities, Gross Unrealized Losses	-2	-1
Marketable Securities, Fair Value	16,914	6,652
Long-term Marketable Securities | Asset-backed Securities | Minimum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'1 year	'1 year
Long-term Marketable Securities | Asset-backed Securities | Maximum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'2 years	'2 years
Long-term Marketable Securities | Securities of U.S. government-sponsored agencies	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	5,999	'
Marketable Securities, Gross Unrealized Gains	1	'
Marketable Securities, Gross Unrealized Losses	-2	'
Marketable Securities, Fair Value	$5,998	'
Long-term Marketable Securities | Securities of U.S. government-sponsored agencies | Minimum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'1 year	'
Long-term Marketable Securities | Securities of U.S. government-sponsored agencies | Maximum	'	'
Schedule of Marketable Securities	'	'
Available For Sale Securities Contractual Maturity	'2 years	'

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (Fair Value, Measurements, Recurring, USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	$55,735	$20,363
Acquisition-related contingent consideration	14,515	14,177
Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	52,077	800
Acquisition-related contingent consideration	0	0
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	3,658	19,563
Acquisition-related contingent consideration	0	0
Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	0	0
Acquisition-related contingent consideration	14,515	14,177
Municipal Bonds | Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	32,095	89,660
Municipal Bonds | Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Municipal Bonds | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	32,095	89,660
Municipal Bonds | Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Corporate Debt Securities | Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	79,514	53,089
Corporate Debt Securities | Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Corporate Debt Securities | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	79,514	53,089
Corporate Debt Securities | Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Commercial Paper | Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	41,422	36,089
Commercial Paper | Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Commercial Paper | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	41,422	36,089
Commercial Paper | Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Asset-backed Securities | Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	17,301	6,652
Asset-backed Securities | Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Asset-backed Securities | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	17,301	6,652
Asset-backed Securities | Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Securities of U.S. government-sponsored agencies | Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	5,998	'
Securities of U.S. government-sponsored agencies | Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	'
Securities of U.S. government-sponsored agencies | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	5,998	'
Securities of U.S. government-sponsored agencies | Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	$0	'

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw Materials	$2,175	$1,369
Work in process	2,589	2,820
Finished goods	72,666	66,161
Total inventories	$77,430	$70,350

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Compensation and other employee-related costs	$16,609	$17,428
Legal and other settlements and expenses	26,044	23,765
Non-income taxes	4,502	2,938
Other	8,451	6,994
Total accrued expenses	$55,606	$51,125

DEBT_Details

DEBT (Details) (Revolving Credit Facility, USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Debt Instrument	'
Credit facility, current borrowing capacity	$50
Credit facility, maximum borrowing capacity	75
Line of Credit, Termination Period Without Penalty	'10 days
Fluctuating Rate Per Annum	'
Debt Instrument	'
Credit facility, variable rate	'LIBOR
Credit facility, period of variable rate	'1 month
Credit facility, basis spread on variable rate	0.75%
Fixed Rate	'
Debt Instrument	'
Credit facility, variable rate	'LIBOR
Credit facility, basis spread on variable rate	0.75%
Fixed Rate | Minimum	'
Debt Instrument	'
Credit facility, period of variable rate	'1 month
Fixed Rate | Maximum	'
Debt Instrument	'
Credit facility, period of variable rate	'3 months
Letter of Credit	'
Debt Instrument	'
Credit facility, maximum borrowing capacity	$25

EQUITY_Textuals_Details

EQUITY (Textuals) (Details)	Sep. 30, 2014	Dec. 31, 2013
Class of Stock	'	'
Common stock, shares authorized	785,000,000	785,000,000
Common Class A	'	'
Class of Stock	'	'
Common stock, shares authorized	500,000,000	'
Common Class B	'	'
Class of Stock	'	'
Common stock, shares authorized	275,000,000	'
Common Class C	'	'
Class of Stock	'	'
Common stock, shares authorized	10,000,000	'

EQUITY_Schedule_of_Issued_and_

EQUITY (Schedule of Issued and Outstanding Shares) (Details)	Sep. 30, 2014	Dec. 31, 2013
Class of Stock	'	'
Common stock, shares issued	94,464,265	93,442,753
Common stock, shares outstanding	94,464,265	93,442,753
Class A Common	'	'
Class of Stock	'	'
Common stock, shares issued	70,586,709	66,065,197
Common stock, shares outstanding	70,586,709	66,065,197
Class B Common	'	'
Class of Stock	'	'
Common stock, shares issued	23,877,556	27,377,556
Common stock, shares outstanding	23,877,556	27,377,556

EQUITY_Stockholders_Equity_Rol

EQUITY Stockholders' Equity Rollforward (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Increase (Decrease) in Stockholders' Equity	'	'	'	'
Total equity, beginning of period	'	'	$472,360	'
Net income	23,061	20,310	64,847	47,627
Stock-based compensation	'	'	5,211	'
Exercise of stock options	'	'	7,644	'
Excess tax benefit of nonqualified stock options	'	'	4,044	'
Other comprehensive loss	-440	247	-298	-358
Total equity, end of period	$553,808	'	$553,808	'

EQUITY_Accumulated_Other_Compr1

EQUITY Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Accumulated other comprehensive income/(loss), net of tax	($1,307)	($1,125)	($1,307)	($1,125)	($1,009)	($767)
Other comprehensive loss before reclassifications	'	'	-305	-354	'	'
Amounts reclassified from accumulated other comprehensive income, net of tax	'	'	7	-4	'	'
Other comprehensive income/(loss), net of tax	-440	247	-298	-358	'	'
Foreign Currency Translation Adjustment	'	'	'	'	'	'
Accumulated other comprehensive income/(loss), net of tax	-1,331	-1,138	-1,331	-1,138	-1,041	-767
Other comprehensive loss before reclassifications	'	'	-290	-371	'	'
Amounts reclassified from accumulated other comprehensive income, net of tax	'	'	0	0	'	'
Other comprehensive income/(loss), net of tax	'	'	-290	-371	'	'
Unrealized Gain/(Loss) on Marketable Securities, Net of Tax	'	'	'	'	'	'
Accumulated other comprehensive income/(loss), net of tax	24	13	24	13	32	0
Other comprehensive loss before reclassifications	'	'	-15	17	'	'
Amounts reclassified from accumulated other comprehensive income, net of tax	'	'	7	-4	'	'
Other comprehensive income/(loss), net of tax	'	'	($8)	$13	'	'

STOCKBASED_COMPENSATION_Textua

STOCK-BASED COMPENSATION (Textuals) (Details) (USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award	'
Number of stock plans	3
Stock Options	'
Share-based Compensation Arrangement by Share-based Payment Award	'
Maximum contractual term	'10 years
Award vesting period (in years)	'4 years
Unrecognized compensation expense, unvested stock options	$15.50
Weighted average period of recognition, unvested stock options	'3 years
2012 Equity Incentive Plan	'
Share-based Compensation Arrangement by Share-based Payment Award	'
Base number of shares that may be issuable under stock plan	3,076,923
2012 Equity Incentive Plan | Maximum	'
Share-based Compensation Arrangement by Share-based Payment Award	'
Number of shares available for grant	10,769,230
Annual percentage limit for incremental shares that may be issued	3.00%
2012 Equity Incentive Plan | Common Class A	'
Share-based Compensation Arrangement by Share-based Payment Award	'
Number of shares available for grant	6,277,749

STOCKBASED_COMPENSATION_Grant_

STOCK-BASED COMPENSATION (Grant Date Fair Values of Options Awarded to Employees) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'
Weighted average grant date per share fair value	$7.73	$7.17	$9.88	$6.05

STOCKBASED_COMPENSATION_Stock_

STOCK-BASED COMPENSATION (Stock Option Activity) (Details) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding	'
Number of shares outstanding beginning balance	4,886
Number of shares granted	1,167
Number of shares exercised	-1,022
Number of shares forfeited	-190
Number of shares outstanding ending balance	4,841
Number of shares exercisable	2,473
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	'
Weighted average exercise price per share outstanding beginning balance	$10.04
Weighted average exercise price per share granted	$23.73
Weighted average exercise price per share exercised	$7.48
Weighted average exercise price per share forfeited	$15.12
Weighted average exercise price per share outstanding ending balance	$13.69
Weighted average exercise price per share exercisable	$8.76
Weighted average remaining contractual life outstanding	'7 years 1 month 6 days
Weighted average remaining contractual life exercisable	'5 years 6 months 0 days
Aggregate intrinsic value outstanding	$33,679
Aggregate intrinsic value exercisable	$26,984

STOCKBASED_COMPENSATION_Compen

STOCK-BASED COMPENSATION (Compensation Expense Related to Stock Options and Their Intrinsic Values) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'
Compensation expense related to stock options	$1,661	$1,387	$5,211	$3,865
Intrinsic value of stock options exercised	$853	$5,027	$16,750	$22,326

INCOME_TAXES_Details

INCOME TAXES (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Effective income tax rate	33.70%	31.60%	34.60%	32.10%
Effective tax rate, estimated impact for legislation not yet enacted	'	'	0.80%	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Jul. 31, 2011

Jul. 31, 2011

Oct. 31, 2010

Oct. 31, 2010

Dec. 31, 2013

Sep. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

NuVasive, Inc. Litigation

NuVasive, Inc. Litigation

Bianco

Bianco

Altus Partners, LLC Litigation

N-Spine and Synthes Litigation

claim

Minimum

claim

Minimum

Minimum

claim

claim

claim

Loss Contingencies

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency, Pending Claims, Number

'

'

'

'

'

'

3

1

3

1

'

'

'

1

Damages awarded

'

'

'

'

'

$16,000,000

'

'

'

'

'

'

'

'

Combined litigation loss

'

'

'

'

'

19,500,000

'

'

'

'

4,300,000

'

'

'

Royalty Rate

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

Provision for litigation - cost of goods sold

0

0

0

1,260,000

'

1,300,000

'

'

'

'

'

'

'

'

Provision for litigation

$46,000

$99,000

$3,899,000

$18,418,000

$500,000

$18,200,000

'

'

'

'

'

'

$2,000,000

'

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Related Party Transactions [Abstract]	'	'	'	'	'
Accounts payable to related-party	$3,945	'	$3,945	'	$2,656
Purchases from related-party supplier	$5,163	$4,478	$15,954	$15,987	'

SEGMENT_AND_GEOGRAPHIC_INFORMA2

SEGMENT AND GEOGRAPHIC INFORMATION (Geographic Location) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues from External Customers	'	'	'	'
Total sales	$117,787	$107,187	$345,570	$319,214
United States	'	'	'	'
Revenues from External Customers	'	'	'	'
Total sales	106,601	98,109	309,937	292,487
International	'	'	'	'
Revenues from External Customers	'	'	'	'
Total sales	$11,186	$9,078	$35,633	$26,727

SEGMENT_AND_GEOGRAPHIC_INFORMA3

SEGMENT AND GEOGRAPHIC INFORMATION (Products) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			categories
			segments
Revenue from External Customer	'	'	'	'
Total sales	$117,787	$107,187	$345,570	$319,214
Textuals [Abstract]	'	'	'	'
Number of reportable segments	'	'	1	'
Number of product categories	'	'	2	'
Innovative Fusion	'	'	'	'
Revenue from External Customer	'	'	'	'
Total sales	67,726	62,620	200,356	186,929
Disruptive Technology	'	'	'	'
Revenue from External Customer	'	'	'	'
Total sales	$50,061	$44,567	$145,214	$132,285

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Subsequent Event, USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Oct. 23, 2014
Subsequent Event	'	'
Subsequent Event	'	'
Business Acquisition, Percentage of Voting Interests Acquired	'	100.00%
Business Combination, Milestone payments, Maximum	'	$15
Payments to Acquire Businesses, Net of Cash Acquired	$35	'